✦ LIBER ✦

O-279 A multicenter randomised phase II study of cisplatin, etoposide, gemcitabine (PEG) versus cisplatin, gemcitabine (PG) as first line treatment in patients with small cell lung cancer (SCLC): Preliminary results

✍ Scribed by De Marinis, Filippo; Gridelli, Cesare; Lombardo, Marco; Paoluzzi, Luca; Ferraù, Francisco; Barbera, Santi; Bertetto, Oscar; Berni, Sandro; La Bianca, Roberto; Nelli, Fabrizio

Book ID: 118571669
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 339 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)91937-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicenter, randomized, Phase II stud

A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma

✍ Filippo De Marinis; Fabrizio Nelli; Marco Lombardo; Francesco Ferraú; Santi Barb 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and toxicity of combined cisplatin, etoposide, and gemcitabine (PEG) and combined cisplatin plus gemcitabine (PG) in previously untreated patients with extensive‐stage and poor‐prognosis limited‐stage small‐cell lun

Paclitaxel-cisplatin-etoposide (TEP) ver

Paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as first line treatment in small cell lung cancer (SCLC): a preliminary analysis of a multicenter randomized phase III trial

✍ D. Mavroudis; E. Papadakis; M. Veslemes; M. Agelidou; M. Toubis; A. Agelidou; J. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 146 KB

A multicenter randomized phase III study

A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC)

✍ Mavroudis, D; Papadakis, E; Veslemes, M; Agelidou, M; Tsiafaki, X; Agelidou, G; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Phase II study of liposomal cisplatin (L

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

✍ Mylonakis, N.; Athanasiou, A.; Ziras, N.; Angel, J.; Rapti, A.; Lampaki, S.; Pol 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 506 KB

Cisplatin (P), etoposide (E) and gemcita

Cisplatin (P), etoposide (E) and gemcitabine (G), in untreated patients with small cell lung cancer (SCLC): Preliminary results of a multi-institutional phase II trial

✍ De Marinis, F; Cortesi, E; Paoluzzi, L; Cipri, A; Portalone, L; Nelli, F; Giampa 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 113 KB

A phase II/III randomised comparison of

A phase II/III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC)

✍ Robin, R.M; James, L.E; Gower, N.H; Gregory, W; Eisen, T.Q; Harper, P.G; Gilliga 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 211 KB